2. Action at 42 nicotine receptor
Partial agonist/antagonist
Releases lower amounts of dopamine into
brain than smoke
• Reduces withdrawal
• Not as addictive as smoke
Blocks nicotine from binding to receptor
• Prevents reward of smoking
3. Farmacocinética
Concentración Vida media 17-
máxima 4h 24h
Mucosa
Excreción renal
gástrica
Vareniclina
15. Varenicline 12 semaines + si succès encore
12 semaines varenicline ou placebo
80
71
70
60
50
50 12 sem +
placebo
40
12+12 sem
30
20
10
0
Communiqué de presse du 15 nov 2005,
Pfizer
16.
17. Increased CV risk with smoking cessation
drug varenicline: New meta-analysis
Sources
1. Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated with
varenicline: a systematic review and meta-analysis. CMAJ 2011. Available at:http://www.cmaj.ca
2. Hays JT. Varenicline for smoking cessation: Is it a heartbreaker? CMAJ 2011.